Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITPR3 | Q14573 | 8/20 | 0.77 |
| ▸ | ITPR2 | Q14571 | 4/20 | 0.72 |
| ▸ | ITPR1 | Q14643 | 4/20 | 0.72 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.72 |
| ▸ | AKT1 | P31749 | 1/20 | 0.72 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.71 |
| ▸ | INPP5A | Q14642 | 3/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phytic Acid SCHEMBL9164308 | 1.00 | ITPR3 (0.77) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| Phytic Acid SCHEMBL1681470 | 1.00 | ITPR3 (0.77) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| Phytic Acid SCHEMBL17006482 | 1.00 | ITPR3 (0.77) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| Phytic Acid SCHEMBL9741350 | 1.00 | ITPR3 (0.77) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| Phytic Acid SCHEMBL141097 | 1.00 | ITPR3 (0.77) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| Phytate SCHEMBL136587 | 1.00 | ITPR3 (0.77) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| Phytic Acid SCHEMBL9325946 | 1.00 | ITPR3 (0.77) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| Phytic Acid SCHEMBL15374707 | 1.00 | ITPR3 (0.77) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| Phytic Acid SCHEMBL12138455 | 1.00 | ITPR3 (0.77) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| Phytic Acid SCHEMBL1681701 | 1.00 | ITPR3 (0.77) | ITPR3ITPR2ITPR1INPPL1AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2311445-A1 | Methods of preventing, treating and diagnosing disorders of protein aggregation | McLaurin, Joanne (CA) | 2011-04-20 | — | — | EP | claimed |
| US-7521481-B2 | administering to subject a pharmaceutically effective amount of inositol stereoisomers, enantiomers or derivatives thereof; for treating or preventing condition of central or peripheral nervous system or systemic organ associated with a disorder in protein folding or aggregation, or amyloid formation | MCLAURIN JOANNE | 2009-04-21 | — | — | US | claimed |
| US-9833420-B2 | Methods of preventing, treating, and diagnosing disorders of protein aggregation | MCLAURIN JOANNE (CA) | 2017-12-05 | — | — | US | disclosed |
| US-20150164821-A1 | METHODS OF PREVENTING, TREATING, AND DIAGNOSING DISORDERS OF PROTEIN AGGREGATION | MCLAURIN JOANNE (CA) | 2015-06-18 | — | — | US | disclosed |
| US-20150031776-A1 | METHOD OF PREVENTING, TREATING AND DIAGNOSING DISORDERS OF PROTEIN AGGREGATION | MCLAURIN JOANNE (CA) | 2015-01-29 | — | — | US | disclosed |
| EP-2823813-A1 | Methods of preventing, treating and diagnosing disorders of protein aggregation | McLaurin, Joanne (CA) | 2015-01-14 | — | — | EP | disclosed |
| EP-2153829-B1 | Methods of preventing, treating and diagnosing disorders of protein aggregation | MCLAURIN JOANNE (CA) | 2014-08-13 | — | — | EP | disclosed |
| EP-2311445-B1 | Methods of preventing, treating and diagnosing disorders of protein aggregation | MCLAURIN JOANNE (CA) | 2014-03-26 | — | — | EP | disclosed |
| US-20140073701-A1 | METHODS OF PREVENTING, TREATING AND DIAGNOSING DISORDERS OF PROTEIN AGGREGATION | MCLAURIN JOANNE (CA) | 2014-03-13 | — | — | US | disclosed |
| US-20120157549-A1 | METHODS OF PREVENTING, TREATING AND DIAGNOSING DISORDERS OF PROTEIN AGGREGATION | MCLAURIN JOANNE (CA) | 2012-06-21 | — | — | US | disclosed |
| EP-2349233-A1 | USE OF SCYLLO-INOSITOLS FOR THE TREATMENT OF MACULAR DEGENERATION-RELATED DISORDERS | Waratah Pharmaceuticals, Inc. (CA) | 2011-08-03 | — | — | EP | disclosed |
| EP-2311445-A1 | Methods of preventing, treating and diagnosing disorders of protein aggregation | McLaurin, Joanne (CA) | 2011-04-20 | — | — | EP | disclosed |
| US-20100093648-A1 | TREATMENT OF MACULAR DEGENERATION-RELATED DISORDERS | WARATAH PHARMACEUTICALS INC. (CA) | 2010-04-15 | — | — | US | disclosed |
| WO-2010040232-A1 | USE OF SCYLLO-INOSITOLS FOR THE TREATMENT OF MACULAR DEGENERATION-RELATED DISORDERS | WARATAH PHARMACEUTICALS INC. (CA) | 2010-04-15 | — | — | WO | disclosed |
| EP-2153829-A1 | Methods of preventing, treating and diagnosing disorders of protein aggregation | McLaurin, Joanne (CA) | 2010-02-17 | — | — | EP | disclosed |
| US-20090227686-A1 | METHODS OF PREVENTING, TREATING AND DIAGNOSING DISORDERS OF PROTEIN AGGREGATION | MCLAURIN JOANNE | 2009-09-10 | — | — | US | disclosed |
| EP-1608350-B1 | METHODS OF PREVENTING, TREATING AND DIAGNOSING DISORDERS OF PROTEIN AGGREGATION | MCLAURIN JOANNE (CA) | 2009-06-03 | — | — | EP | disclosed |
| US-7521481-B2 | administering to subject a pharmaceutically effective amount of inositol stereoisomers, enantiomers or derivatives thereof; for treating or preventing condition of central or peripheral nervous system or systemic organ associated with a disorder in protein folding or aggregation, or amyloid formation | MCLAURIN JOANNE | 2009-04-21 | — | — | US | disclosed |
| US-20040204387-A1 | administering to subject a pharmaceutically effective amount of inositol stereoisomers, enantiomers or derivatives thereof; for treating or preventing condition of central or peripheral nervous system or systemic organ associated with a disorder in protein folding or aggregation, or amyloid formation | MCLAURIN JOANNE (CA) | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227686-A1 | METHODS OF PREVENTING, TREATING AND DIAGNOSING DISORDERS OF PROTEIN AGGREGATION | TTR, IAPP, PRNP | ITPR3 669/4885ITPR2 464/4885ITPR1 553/4885 |
| US-20120157549-A1 | METHODS OF PREVENTING, TREATING AND DIAGNOSING DISORDERS OF PROTEIN AGGREGATION | TTR, IAPP, PRNP | ITPR3 669/4885ITPR2 464/4885ITPR1 553/4885 |
| US-20040204387-A1 | administering to subject a pharmaceutically effective amount of inositol stereoisomers, enantiomers or derivatives thereof; for treating or preventing condition of central or peripheral nervous system or systemic organ associated with a disorder in protein folding or aggregation, or amyloid formation | IAPP, PLPBP, PPIP5K2 | ITPR3 67/4885ITPR2 39/4885ITPR1 58/4885 |
| US-20150164821-A1 | METHODS OF PREVENTING, TREATING, AND DIAGNOSING DISORDERS OF PROTEIN AGGREGATION | TTR, APP, IAPP | ITPR3 650/4885ITPR2 458/4885ITPR1 519/4885 |
| US-20100093648-A1 | TREATMENT OF MACULAR DEGENERATION-RELATED DISORDERS | PDE6C, PDE6D, PDE6A | ITPR3 65/4885ITPR2 80/4885ITPR1 100/4885 |
| US-20150031776-A1 | METHOD OF PREVENTING, TREATING AND DIAGNOSING DISORDERS OF PROTEIN AGGREGATION | TTR, IAPP, APP | ITPR3 545/4885ITPR2 342/4885ITPR1 429/4885 |
| US-20140073701-A1 | METHODS OF PREVENTING, TREATING AND DIAGNOSING DISORDERS OF PROTEIN AGGREGATION | TTR, IAPP, PRNP | ITPR3 669/4885ITPR2 464/4885ITPR1 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.